-+ 0.00%
-+ 0.00%
-+ 0.00%

ARROWHEAD PHARMACEUTICALS - PLOZASIRAN DEMONSTRATED FAVORABLE SAFETY AND TOLERABILITY PROFILE IN PHASE 3 STUDIES

Reuters·08/30/2026 15:30:03

Please log in to view news